ASCO 2022 Conference Coverage

 

GI
10:11

ASCO 2022 Conference Coverage

ASCO 2022 on Atezolizumab + Bevacizumab vs Lenvatinib or Sorafenib in Non-Viral Unresectable HCC: An International Study

FEATURING Margherita Rimini
  • 278 views
  • August 5, 2022
  • 3
07:56

ASCO 2022 Conference Coverage

ASCO 2022 on RAS Co-Mutation and Early Onset Disease Represent an Aggressive Phenotype of Atypical (Non-V600) BRAF Mutant mCRC

FEATURING Benny Johnson
  • 97 views
  • July 28, 2022
03:33

ASCO 2022 Conference Coverage

ASCO 2022 Patient-Reported Outcomes From the Phase 3 HIMALAYA Study of Tremelimumab + Durvalumab in Unresectable HCC

FEATURING Peter Galle
  • 73 views
  • July 9, 2022
02:15

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Adjuvant Chemotherapy Guided by ctDNA Analysis in Stage II Colon Cancer: The Randomized DYNAMIC Trial

FEATURING Jeanne Tie
  • 18 views
  • July 7, 2022
07:51

ASCO 2022 Conference Coverage

Updates on the PARADIGM Trial: PAN + mFOLFOX6 vs. BEV + mFOLFOX6 as 1L in Pts With RAS WT mCRC

FEATURING Takayuki Yoshino
  • 161 views
  • July 5, 2022
01:21

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Phase 3 CAIRO5 Study: FOLFOXIRI + Bev vs. FOLFOX/FOLFIRI + Bev in Initially Unresectable Colorectal Liver Metastases and Right-Sided and/or RAS/BRAFV600Em Primary Tumor

FEATURING Cornelis Punt
  • 20 views
  • June 29, 2022
07:57

ASCO 2022 Conference Coverage

ASCO 2022 on Phase I/II Trial of Encorafenib, Cetuximab, & Nivolumab in Patients With MSS BRAFV600E mCRC

FEATURING Van Morris
  • 342 views
  • June 28, 2022
  • 1
59

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Phase I/II Trial of Encorafenib, Cetuximab, & Nivolumab in Patients With MSS BRAFV600E mCRC

FEATURING Van Morris
  • 14 views
  • June 28, 2022
07:35

ASCO 2022 Conference Coverage

ASCO 2022 on an Open-Label, Multicenter, Randomized Phase II Study of Atezolizumab & Bevacizumab With Y90 TARE in Unresectable HCC

FEATURING Aiwu Ruth He, Filip Banovac
  • 238 views
  • June 23, 2022
40

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on an Open-Label, Multicenter, Randomized Phase II Study of Atezolizumab & Bevacizumab With Y90 TARE in Unresectable HCC

FEATURING Aiwu Ruth He, Filip Banovac
  • 15 views
  • June 23, 2022
58

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on EA2183: A Phase III Study of Consolidative RT in Patients With Oligometastatic HER2- Esophageal & Gastric Adenocarcinoma

FEATURING Nataliya Uboha
  • 229 views
  • June 21, 2022
  • 2
06:44

ASCO 2022 Conference Coverage

ASCO 2022 on EA2183: A Phase III Study of Consolidative RT in Patients With Oligometastatic HER2- Esophageal & Gastric Adenocarcinoma

FEATURING Nataliya Uboha
  • 511 views
  • June 21, 2022
  • 1
05:40

ASCO 2022 Conference Coverage

ASCO 2022 Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment for HER2+ Gastric and GEJ Adenocarcinoma

FEATURING Daisuke Takahari
  • 130 views
  • June 17, 2022
  • 1
11:07

ASCO 2022 Conference Coverage

ASCO 2022 The Differential Response to Immune Checkpoint Inhibitors in Colorectal and Endometrial Cancer Pts According to Different Mismatch Repair Alterations

FEATURING Moh'd Khushman
  • 88 views
  • June 16, 2022
06:33

ASCO 2022 Conference Coverage

ASCO 2022 Testing of a Machine Learning Model for Ability to Predict Oxaliplatin and Bevacizumab Benefit in NRG Oncology

FEATURING Min Sun
  • 11 views
  • June 16, 2022
05:53

ASCO 2022 Conference Coverage

ASCO 2022 on a Regional Subgroup Analysis of the Phase 3 TOPAZ-1 Study of Durvalumab + Gemcitabine & Cisplatin in Advanced Biliary Tract Cancer

FEATURING Arndt Vogel
  • 153 views
  • June 15, 2022
  • 1
04:54

ASCO 2022 Conference Coverage

ASCO 2022 IMMUTACE - A Biomarker-Orientated Phase II, Single-Arm, Open-Label AIO Study of Transarterial Chemoembolization + Nivo Performed for Intermediate-Stage HCC: Updated Efficacy Results

FEATURING Arndt Vogel
  • 96 views
  • June 15, 2022
05:30

ASCO 2022 Conference Coverage

ASCO 2022 on SWOG S2012: Randomized Phase II/III Trial of 1L Platinum/Etoposide +/- Atezo in Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas

FEATURING David Zhen
  • 9 views
  • June 15, 2022
05:12

ASCO 2022 Conference Coverage

ASCO 2022 IMMUNIB Trial: A Single-Arm, Phase II Study Evaluating Safety & Efficacy of Nivo in Combination With Lenvatinib in Advanced Stage HCC

FEATURING Arndt Vogel
  • 341 views
  • June 15, 2022
  • 3
10:29

ASCO 2022 Conference Coverage

ASCO 2022 Using cfDNA to Identify Guideline-Relevant Biomarkers for Therapy Selection in 14,000 Pts With mCRC

FEATURING Pashtoon Kasi
  • 219 views
  • June 15, 2022
  • 1
58

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Targeting HER2 Mutation-Positive Advanced Biliary Tract Cancers With Neratinib: Final Results From the Phase 2 SUMMIT Basket Trial

FEATURING James Harding
  • 16 views
  • June 15, 2022
54

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on ctDNA Profile in Pancreatic Ductal Adenocarcinoma and Potential Targeted Therapy

FEATURING Francis Esposito
  • 17 views
  • June 15, 2022
09:42

ASCO 2022 Conference Coverage

ASCO 2022 Targeting HER2 Mutation-Positive Advanced Biliary Tract Cancers With Neratinib: Final Results From the Phase 2 SUMMIT Basket Trial

FEATURING James Harding
  • 91 views
  • June 15, 2022
05:39

ASCO 2022 Conference Coverage

ASCO 2022 on ctDNA Profile in Pancreatic Ductal Adenocarcinoma and Potential Targeted Therapy

FEATURING Francis Esposito
  • 885 views
  • June 15, 2022
  • 4
04:22

ASCO 2022 Conference Coverage

ASCO 2022 on the Multicenter Phase Ib US Trial of Salvage CT041 CLDN18.2-Specific CAR T-Cell Therapy for Advanced Gastric and Pancreatic Adenocarcinoma

FEATURING Gregory Botta
  • 140 views
  • June 15, 2022
01:26

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on the Multicenter Phase Ib US Trial of Salvage CT041 CLDN18.2-Specific CAR T-Cell Therapy for Advanced Gastric and Pancreatic Adenocarcinoma

FEATURING Gregory Botta
  • 26 views
  • June 15, 2022
01:13

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Investigating a Switch Maintenance Concept With 5-FU + Bev After FOLFIRI + Cetuximab Induction Treatment vs. Continued Treatment With FOLFIRI + Cetuximab: Report of a Secondary Endpoint of the Phase-III FIRE-4 Study

FEATURING Sebastian Stintzing
  • 24 views
  • June 14, 2022
55

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Perioperative Ramucirumab + FLOT vs. FLOT Alone for Resectable Esophagogastric Adenocarcinoma With High Rate of Signet Cell Component: Final Results of the Multicenter, Randomized Phase II/III Trial

FEATURING Thorsten Oliver Götze
  • 17 views
  • June 14, 2022
07:37

ASCO 2022 Conference Coverage

ASCO 2022 on Investigating a Switch Maintenance Concept With 5-FU + Bev After FOLFIRI + Cetuximab Induction Treatment vs. Continued Treatment With FOLFIRI + Cetuximab: Report of a Secondary Endpoint of the Phase-III FIRE-4 Study

FEATURING Sebastian Stintzing
  • 204 views
  • June 14, 2022
08:49

ASCO 2022 Conference Coverage

ASCO 2022 on the Phase 2/3 Study of an Individualized Neoantigen Vaccine + Immune Checkpoint Blockade as Maintenance for Newly Diagnosed mCRC

FEATURING J. Randolph Hecht
  • 155 views
  • June 13, 2022
  • 1
34

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on the Phase 2/3 Study of an Individualized Neoantigen Vaccine + Immune Checkpoint Blockade as Maintenance for Newly Diagnosed mCRC

FEATURING J. Randolph Hecht
  • 53 views
  • June 13, 2022
  • 1
06:16

ASCO 2022 Conference Coverage

ASCO 2022 on NSABP FC-10: A Phase Ib Study of Pembro + Pemetrexed & Oxaliplatin in Chemo-Refractory mCRC

FEATURING John Krauss
  • 73 views
  • June 13, 2022
34

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on mFOLFOXIRI + PAN vs. mFOLFOX6/PAN as Initial Treatment for Unresectable RAS and BRAF Wild-Type mCRC: Results of the Phase III Randomized TRIPLETE Study by GONO

FEATURING Chiara Cremolini
  • 44 views
  • June 10, 2022
11:34

ASCO 2022 Conference Coverage

ASCO 2022 on mFOLFOXIRI + PAN vs. mFOLFOX6/PAN as Initial Treatment for Unresectable RAS and BRAF Wild-Type mCRC: Results of the Phase III Randomized TRIPLETE Study by GONO

FEATURING Chiara Cremolini
  • 191 views
  • June 10, 2022
09:20

ASCO 2022 Conference Coverage

ASCO 2022 on the Comparative Efficacy of Novel Combination IO Strategies for Unresectable HCC: A Network Meta-Analysis of Landmark Phase III Trials

FEATURING Claudia Fulgenzi
  • 219 views
  • June 10, 2022
40

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Multicenter Phase II Study of Abemaciclib & Ramucirumab in Metastatic Esophageal/GEJ Carcinoma

FEATURING Ronan Kelly
  • 18 views
  • June 10, 2022
05:15

ASCO 2022 Conference Coverage

ASCO 2022 on Multicenter Phase II Study of Abemaciclib & Ramucirumab in Metastatic Esophageal/GEJ Carcinoma

FEATURING Ronan Kelly
  • 234 views
  • June 10, 2022
31

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 NEOPRISM CRC: Neoadjuvant Pembrolizumab Stratified to Tumor Mutation Burden for High-Risk Stage 2/3 Deficient-MMR/MSI-H CRC

FEATURING Kai-Keen Shiu
  • 36 views
  • June 9, 2022
15:40

ASCO 2022 Conference Coverage

ASCO 2022 NEOPRISM CRC: Neoadjuvant Pembrolizumab Stratified to Tumor Mutation Burden for High-Risk Stage 2/3 Deficient-MMR/MSI-H CRC

FEATURING Kai-Keen Shiu
  • 1,136 views
  • June 9, 2022
  • 5
01:02

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Pembrolizumab + mFOLFOX7/FOLFIRI for mCRC in KEYNOTE-651: Long-Term Follow-Up of Cohorts B and D

FEATURING Richard Kim
  • 358 views
  • June 9, 2022
  • 3
08:41

ASCO 2022 Conference Coverage

ASCO 2022 on KEYNOTE-651: Pembrolizumab + mFOLFOX7/FOLFIRI for mCRC: Long-Term Follow-Up of Cohorts B and D

FEATURING Richard Kim
  • 2,345 views
  • June 9, 2022
  • 8
43

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on CRC Metastatic dMMR Immuno-Therapy (COMMIT) Phase 3 Study: Atezo Monotherapy vs. mFOLFOX6/Bevacizumab/Atezo in the 1L Treatment of dMMR/MSI-H mCRC

FEATURING Michael Overman
  • 19 views
  • June 9, 2022
04:11

ASCO 2022 Conference Coverage

ASCO 2022 on CRC Metastatic dMMR Immuno-Therapy (COMMIT) Phase 3 Study: Atezo Monotherapy vs. mFOLFOX6/Bevacizumab/Atezo in the 1L Treatment of dMMR/MSI-H mCRC

FEATURING Michael Overman
  • 1,083 views
  • June 9, 2022
39

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Immunotherapy With Nivolumab After Progression on Lenvatinib in Advanced HCC: A Real-World Indian Experience and Case Report

FEATURING Amit Rauthan
  • 117 views
  • June 8, 2022
  • 1
09:02

ASCO 2022 Conference Coverage

ASCO 2022 Immunotherapy With Nivolumab After Progression on Lenvatinib in Advanced HCC: A Real-World Indian Experience and Case Report

FEATURING Amit Rauthan
  • 235 views
  • June 8, 2022
  • 2
23

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 Updates on Infigratinib vs. Gemcitabine + Cisplatin in Advanced Cholangiocarcinoma With a FGFR2 Gene Fusion/Rearrangement: PROOF 301 Trial

FEATURING Ghassan Abou-Alfa
  • 104 views
  • June 7, 2022
06:42

ASCO 2022 Conference Coverage

ASCO 2022 on PROOF 301 Trial: Updates on Infigratinib vs. Gemcitabine + Cisplatin in Advanced Cholangiocarcinoma With a FGFR2 Gene Fusion/Rearrangement

FEATURING Ghassan Abou-Alfa
  • 1,149 views
  • June 7, 2022
  • 7